Clinical Study
Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
Table 1
Clinical characteristic of patients.
| | Characteristic | Mean ± SD |
| | Age (years) | | | Pathological tumor size (cm) | | | No. of node analyze | | | No. of positive nodes | |
| | | No. (%) |
| | Side involved | | | Right | 26 (44.8) | | Left | 32 (55.2) | | Histology | | | Ductal | 52 (89.7) | | Lobular | 4 (6.9) | | Others | 2 (3.4) | | Hormone receptors | | | ER | | | Positive | 37 (63.8) | | Negative | 21 (36.2) | | PR | | | Positive | 38 (65.5) | | Negative | 20 (34.5) | | HER-2 | | | Positive | 23 (39.7) | | Negative | 35 (60.3) | | Hormone therapy | | | Positive | 45 (77.6) | | Negative | 13 (22.4) | | Regimen of hormone therapy | | | Tamoxifen | 40 (88.9) | | Others | 5 (11.1) |
|
|
